Why Intellectual Property Matters for Patients

02.11.14 | By

The importance of protecting intellectual property cannot be overstated. For the biopharmaceutical industry, ensuring our ability to innovate is essential for continued R&D to help patients live longer, healthier lives.

The Ongoing Battle for Patient Health

02.07.14 | By

Every day there is a war to wage against the world’s most devastating diseases. It is a fight we must win to make the world a safer, healthier place for our patients, and this week we discussed some of the battles currently underway.

Intellectual Property Protection and India

02.06.14 | By

A new study  examines the economic impact of India’s current approach to intellectual property rights as it affects pharmaceutical products and Foreign Direct Investment (FDI).  The study from Sonecon by Robert Shapiro and Aparna Mathur titled “How India Can Attract More Foreign Direct Invest Investment, Create Jobs, and Increase GDP: The Benefits of Respecting the Intellectual Property Rights of Foreign Pharmaceutical Producers” establishes that i

Briefing Assesses Impact of U.S. v. Caronia Ruling on Regulation of Medical Communications, One Year Later

01.31.14 | By

 The Washington Legal Foundation recently convened an enlightening expert roundtable discussion about the impact of late 2012's decision in U.S. vs. Caronia. 

Commitment to Data Sharing

01.30.14 | By

As of January 1, researchers are now able to submit proposals to receive access to patient level data, protocols, and clinical study reports for new medicines approved in the U.S and EU after January 1, 2014.  The biopharmaceutical sector’s commitment to data sharing provides new avenues for the scientific community and patients to benefit from clinical research, while maintaining patient privacy, the integrity of national regulators, and incentives for companies to make long-term investments in biomedical research.
 

On Pharmaceutical Innovation, Intellectual Property Rights, Patient Access and Pricing

01.30.14 | By

Dr. Robert Freeman, Professor of Pharmacy Administration (health services research) in the Department of Pharmacy Practice & Administration at the University of Maryland Eastern Shore School of Pharmacy, comments on the recently released paper from University College London School of Pharmacy on patient’s needs and intellectual property in middle income countries.

PhRMA on the State of the Union Address

Washington, D.C. (January 29, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement:

"President Obama’s address comes at a time when America’s biopharmaceutical research companies are bringing pioneering new medicines to patients, supporting high-value American jobs and helping strengthen local communities and our national economy. Continued progress – the kind that President Obama urged for last night – is only possible, however, if we fully embrace innovation.

I am Research, Progress, Hope: It Takes a Team

01.29.14 | By

Today’s featured scientist comes from Agensys, a subsidiary of Astellas, where she is working on developing a treatment or cure for different types of cancers.

Looking Past 'Can vs. Can’t'

01.28.14 | By

The great inventor and businessman Henry Ford once said, “Whether you think you can, or think you can’t – you’re right."

Getting the Facts on Cost of Medicines

01.28.14 | By

When looking at an issue as important and complex as health care costs in the U.S., it’s critical that full facts, not select data, lead the discussion. Drew Armstrong’s recent article about a Hepatitis C medicine paints an incomplete picture of our health care system and further propels inaccurate information about prescription medicines.

Pages

Subscribe to RSS - Opinion